Kilitch Drugs (India) Ltd Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 2
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Expecting 20%-25% growth in sales for FY 2025 over FY 2024.
- Overall year-on-year growth forecasted at approximately 25%-30% for FY 2025.
- Export market expected to contribute around 60%-65% of revenue, domestic market around 30%-40%.
- Expansion of Khopoli plant (INR 100 crores investment) to start operations with validation by May 2025, producing:
- - Oral tablets: approx. 260 million units/year
- - Liquid injectable vials: approx. 31 million units/year
- - Liquid injectable ampoules: approx. 47 million units/year
- New facility designed considering client demand, especially near Mumbai for better QA audits and logistics.
- Ethiopian facility utilization expected to reach around 60% capacity in FY 2024 with government tenders boosting revenues.
- Continued focus on product development and launching new products, especially for export markets like Kenya starting FY 2025.
See what Kilitch Drugs (India) Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or future fundraising through debt or equity in the transcript.
- The management discusses working capital utilization and capex but does not indicate plans for new debt or equity fundraising.
- They highlight working capital pressures being managed through internal funds and government tenders.
- Asset monetization (land parcel valued around INR50 crores) is being considered, which may generate funds internally, not through equity or debt.
- No direct reference to raising funds via equity issuance or new borrowings was made during the Q&A or management remarks.
See what Kilitch Drugs (India) Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Kilitch Drugs is investing around INR 100 crores to develop a new greenfield pharmaceutical project at Khopoli, Maharashtra, India.
- The Khopoli plant is designed to produce:
- - Oral tablets with a capacity of approx. 260 million per year
- - Liquid injectable vials approx. 31 million per year
- - Liquid injectable ampoules approx. 47 million per year
- - Ophthalmic drops approx. 21.4 million per year
- - Nasal drops approx. 21.4 million per year
- The building construction at the Mumbai plant has started; they expect to complete the first floor slab by end of the current month.
- Validation and production commencement is planned by May 25, 2024, in phased manner (Phase 1, 2, 3).
- Capex of around INR 50 crores was incurred for the Ethiopian facility till 2021, with production starting in 2021.
- No major capex since then for Ethiopian facility; focus is on utilizing the existing facility and expanding markets.
- Land parcel valued around INR 50 crores being considered for monetization, but no immediate plans to sell.
Track Kilitch Drugs (India) Ltd — get its next earnings analysis in your feed
Margin guidance
Category 2- Kilitch Drugs India Limited expects a revenue growth of around 25%-30% year-on-year for FY 2025.
- EBITDA margins are projected to be maintained or improved in the range of 18%-22%.
- The company targets achieving INR 500 crores in revenue by 2027, with EBITDA margins remaining at approximately 22%-24%.
- The Ethiopian facility is expected to increase capacity utilization to around 60% in the current fiscal year, supporting strong margin expectations of 20%-25% EBITDA in that market.
- New product development, particularly for export markets such as Kenya, is expected to commence in FY 2025, aiding growth and margin improvement.
- The upcoming Khopoli plant, with a capacity for producing 260 million oral tablets and other dosage forms, is planned to start validation by May 2025, contributing to future growth.
- Overall, the company anticipates sustained profitability growth driven by operational expansion and increased export business.
Order book
Yes- Kilitch Drugs has secured a significant government tender in Ethiopia worth USD 9.13 million, which will commence execution from Q2 FY24.
- The company expects this government order to trigger around 60% utilization of their Ethiopian facility capacity for the whole year.
- The facility is expected to run more efficiently and potentially add 20%-30% more orders beyond the government tender.
- For 2025, the new Khopoli plant validation starts May 25, with planned capacity: 260 million oral tablets, 31 million injectable vials, 47 million injectable ampoules annually.
- Demand near Mumbai is driven by client requirements for closer logistics and QA audits, indicating existing and new clients will supply from Khopoli in 2025.
- The company foresees a 25%-30% year-on-year growth for FY25, maintaining a 60%-65% export and 30%-40% domestic sales ratio.
- Private market orders in Ethiopia are expected to increase as currency and government tender issues ease.
How does Kilitch Drugs (India) Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Kilitch Drugs (India) Ltd rank in Pharmaceuticals & Biotechnology?
Compare Kilitch Drugs (India) Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Kilitch Drugs (India) Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…